Early Day List To Watch: CSG Systems International (NASDAQ:CSGS), Paramount Group (NYSE:PGRE), Alnylam Pharmaceuticals (NASDAQ:ALNY), Sequenom (NASDAQ:SQNM)

Posted by on Mar 18, 2016

Agilent Technologies Inc. (NYSE:A) shares moved up 0.80% in last trading session and ended the day at $39.29. A Gross Margin is 51.10% and its has a return on assets of 6.10%. Agilent Technologies Inc. (NYSE:A) quarterly performance is -3.46%.

Agilent Technologies Inc. (NYSE:A) announced that a quarterly dividend of 11.5 cents per share of common stock will be paid on April 27, 2016, to all shareholders of record as of the close of business on April 5, 2016.

CSG Systems International Inc. (NASDAQ:CSGS) ended the last trading day at $42.29. Company weekly volatility is calculated as 4.13% and price to cash ratio as 5.68. CSG Systems International Inc. (NASDAQ:CSGS) showed a weekly performance of 16.44%.

CSG Systems International, Inc. (NASDAQ: CSGS), announced that as a result of its first quarter dividend of $0.1850 per share on its common stock, it will adjust the conversion rate for its outstanding 3.0% Senior Subordinated Convertible Notes issued in March 2010 (the “2010 Convertible Notes”). The adjustments are made in accordance with the terms of the Indenture Agreement.

On 17 March, Paramount Group, Inc. (NYSE:PGRE) shares moved up 1.87% and was closed at $16.34. Paramount Group, Inc. (NYSE:PGRE) year to date (YTD) performance is -9.72%.

Paramount Group, Inc. (NYSE:PGRE) announced that its board of directors has declared a regular quarterly cash dividend of $0.095 per share of common stock for the period from January 1, 2016 to March 31, 2016. The dividend will be payable on April 15, 2016 to stockholders of record as of the close of business on March 31, 2016.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares moved down -4.22% in last trading session and ended the day at $57.84. ALNY has a return on assets of -19.40%. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) quarterly performance is -34.64%.

On 14 March, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), announced that it has initiated dosing of hemophilia patients with inhibitors in Part D of an ongoing Phase 1 clinical trial evaluating a once-monthly subcutaneous dose regimen of fitusiran (ALN-AT3). Patients with hemophilia A with inhibitors and with hemophilia B with inhibitors have now been dosed with fitusiran. Fitusiran is an investigational RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia A and B and rare bleeding disorders (RBD).

Sequenom Inc. (NASDAQ:SQNM) caters to the Healthcare space. It has a net profit margin of -1.60% and weekly performance is -4.61%. On the last day of trading company shares ended up at $1.45.

On 2 March, Sequenom Inc. (NASDAQ:SQNM) reported Revenue for the fourth quarter of 2015 was $27.8 million, compared to $29.9 million for the third quarter of 2015 and $36.8 million for the fourth quarter of 2014. Revenue is recorded primarily on a cash basis, with accrual accounting used for several third-party payors and for client bill arrangements. The decline in revenue in the fourth quarter of 2015 compared to the third quarter is attributed to reimbursement rates and timing of cash collections. Diagnostic services revenue for the fourth quarter of 2015 was approximately $6.6 million lower than the same period in 2014 as a result of the transition of certain customers to licensee status, which contributed to the increase in license fee revenue.

Leave a Reply

Your email address will not be published. Required fields are marked *